Business Description
Esperion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29664W1053
Share Class Description:
LTS:0IIM: Ordinary SharesDescription
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.54 | |||||
| Equity-to-Asset | -1.18 | |||||
| Debt-to-Equity | -0.73 | |||||
| Debt-to-EBITDA | -9.33 | |||||
| Interest Coverage | 0.28 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -5.47 | |||||
| Beneish M-Score | -0.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -48.5 | |||||
| 3-Year EBITDA Growth Rate | 30.7 | |||||
| 3-Year EPS without NRI Growth Rate | 27.1 | |||||
| 3-Year FCF Growth Rate | 28.4 | |||||
| 3-Year Book Growth Rate | -1.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 60.69 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.75 | |||||
| 9-Day RSI | 33.35 | |||||
| 14-Day RSI | 39.83 | |||||
| 3-1 Month Momentum % | 23.15 | |||||
| 6-1 Month Momentum % | -15.89 | |||||
| 12-1 Month Momentum % | 56.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.85 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 0.87 | |||||
| Days Inventory | 475.82 | |||||
| Days Sales Outstanding | 67.68 | |||||
| Days Payable | 226.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -65.8 | |||||
| Shareholder Yield % | -21.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.58 | |||||
| Operating Margin % | 5.57 | |||||
| Net Margin % | -29.37 | |||||
| FCF Margin % | -8.83 | |||||
| ROA % | -29.58 | |||||
| ROIC % | 31.11 | |||||
| 3-Year ROIIC % | -217.86 | |||||
| ROC (Joel Greenblatt) % | -502.3 | |||||
| ROCE % | -21.65 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 7.03 | |||||
| PS Ratio | 1.35 | |||||
| EV-to-EBIT | -19.65 | |||||
| EV-to-Forward-EBIT | 1.71 | |||||
| EV-to-EBITDA | -19.68 | |||||
| EV-to-Forward-EBITDA | 1.71 | |||||
| EV-to-Revenue | 1.92 | |||||
| EV-to-Forward-Revenue | 0.85 | |||||
| EV-to-FCF | -21.77 | |||||
| Price-to-GF-Value | 0.74 | |||||
| Earnings Yield (Greenblatt) % | -5.09 | |||||
| FCF Yield % | -5.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Esperion Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 295.451 | ||
| EPS (TTM) ($) | -0.64 | ||
| Beta | 1.82 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 143.39 | ||
| 14-Day RSI | 39.83 | ||
| 14-Day ATR ($) | 0.334291 | ||
| 20-Day SMA ($) | 2.80562 | ||
| 12-1 Month Momentum % | 56.68 | ||
| 52-Week Range ($) | 1.5805 - 3.855 | ||
| Shares Outstanding (Mil) | 197.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Esperion Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Esperion Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Esperion Therapeutics Inc Frequently Asked Questions
What is Esperion Therapeutics Inc(LTS:0IIM)'s stock price today?
The current price of LTS:0IIM is $2.15. The 52 week high of LTS:0IIM is $3.86 and 52 week low is $1.58.
When is next earnings date of Esperion Therapeutics Inc(LTS:0IIM)?
The next earnings date of Esperion Therapeutics Inc(LTS:0IIM) is 2025-02-27 Est..
Does Esperion Therapeutics Inc(LTS:0IIM) pay dividends? If so, how much?
Esperion Therapeutics Inc(LTS:0IIM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers